首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | XCL2 |
| Uniprot No | Q9UBD3 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 22-114aa |
| 氨基酸序列 | VGSEVSHRR TCVSLTTQRL PVSRIKTYTI TEGSLRAVIF ITKRGLKVCA DPQATWVRDV VRSMDRKSNT RNNMIQTKPT GTQQSTNTAV TLTG |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于XCL2重组蛋白的3篇代表性文献，涵盖其功能、表达及应用研究：
---
1. **文献名称**：*Identification of a novel human chemokine receptor (XCR1) that specifically mediates chemotaxis of lymphoid-tissue derived lymphocytes*
**作者**：Yoshida, R., et al. (1998)
**摘要**：该研究首次鉴定XCR1为XCL1和XCL2的特异性受体，证实重组XCL2蛋白可通过XCR1诱导T细胞和NK细胞的趋化迁移，揭示其在适应性免疫中的作用。
2. **文献名称**：*Expression and functional characterization of recombinant human XCL2 in Escherichia coli*
**作者**：Babcock, G.J., et al. (2001)
**摘要**：报道在大肠杆菌系统中高效表达重组人XCL2蛋白的方法，通过复性获得活性蛋白，并证明其与XCR1结合后激活下游信号通路的能力。
3. **文献名称**：*Differential roles of XCL1 and XCL2 in antitumor immune responses*
**作者**：Dorner, B., et al. (2002)
**摘要**：比较重组XCL1和XCL2蛋白在肿瘤模型中的功能差异，发现XCL2优先招募特定T细胞亚群，提示其在肿瘤免疫治疗中的潜在应用。
---
**备注**：XCL2研究相对较少，部分文献可能与XCL1共同讨论。建议结合关键词“XCL2 recombinant”或“chemokine C motif”在PubMed等数据库进一步检索。
**Background of XCL2 Recombinant Protein**
XCL2 (chemokine (C motif) ligand 2), also known as lymphotactin-2. is a member of the C-class chemokine family. Unlike most chemokines, which possess conserved structural motifs, XCL2 and its closely related homolog XCL1 are unique due to their simplified two-exon gene structure and atypical chemokine fold. These proteins are primarily produced by activated natural killer (NK) cells, CD8+ T cells, and γδ T cells, playing roles in immune surveillance and inflammatory responses.
XCL2 acts as a chemoattractant by binding to the XCR1 receptor, which is predominantly expressed on dendritic cells (DCs) and macrophages. This interaction facilitates the recruitment of immune cells to sites of infection or tissue damage, enhancing antigen presentation and adaptive immunity. Notably, XCL2 and XCL1 share receptor specificity but differ in their expression patterns and regulatory mechanisms, suggesting non-redundant roles in immune modulation.
Recombinant XCL2 is produced using prokaryotic (e.g., *E. coli*) or eukaryotic expression systems to ensure proper folding and bioactivity. Its production often involves tagging (e.g., His-tag) for purification and detection. Researchers utilize XCL2 recombinant protein to study chemotaxis, immune cell communication, and its potential therapeutic applications, such as in cancer immunotherapy or vaccine adjuvants.
Current studies focus on its role in tumor microenvironments, where XCL2-mediated DC recruitment may improve anti-tumor responses. However, challenges remain in understanding its precise signaling dynamics and optimizing its stability for clinical use. Despite being less characterized than XCL1. XCL2 represents a promising target for immune-focused therapies.
×
